Osteoporosis Treatment: Side Effects, Risks, and Real Data

An Evidence-Based Guide for Informed Patients (2025)

Purpose: Answer factual questions about side effect rates, separate documented risks from anecdotal reports, and provide the quantitative data needed for an informed decision.

The Core Question: Do These Medicines Cause “Shattered Bones”?

Short answer: No. The “brittle bone” narrative misinterprets a rare, specific side effect. Here is what the data actually shows.

Atypical Femur Fractures (AFF): The Real Numbers

What it is: A specific type of thigh bone break that occurs below the hip joint, distinct from typical osteoporotic hip fractures. Characterized by transverse (straight-across) breaks rather than comminuted (crushed) patterns.

Actual incidence with bisphosphonates:

1 to 10 per 10,000 patient-years with long-term use (>5 years)
Risk increases with duration: minimal in years 1-3, rises after year 5
Source: PMIDs 34679224, 27179251

Context for comparison:

Untreated osteoporosis causes approximately 300-500 hip fractures per 10,000 high-risk women over 5 years
Bisphosphonates prevent 40-53% of these typical fractures
Net effect: For every 1 atypical fracture caused, approximately 50-100 typical hip fractures are prevented

Publication bias note: Early case reports suggested higher AFF rates. A 2024 analysis found high risk of publication bias; actual rates are likely at the lower end of early estimates due to selective reporting of severe cases. Source

Mechanism (not “shattered bones”):

Bisphosphonates suppress osteoclasts, which both break down bone AND repair microdamage. After years of suppression, microcracks accumulate in cortical bone without repair. This creates a specific fracture pattern; not general brittleness. Source

Denosumab (Prolia): The Rebound Fracture Risk Quantified

The problem: Stopping denosumab without sequential therapy causes a rapid, dangerous spike in bone turnover.

Documented rates:

Approximately 1 in 14 patients (7.1%) who discontinue without follow-up therapy suffer multiple vertebral fractures within 7-12 months
Bone turnover markers rise above baseline within 3 months
All BMD gains lost within 12 months
Sources: PMIDs 39448137, 36088628

What “multiple vertebral fractures” means:

Not one fracture; several spine fractures occurring in sequence over months. These are painful, cause height loss and deformity, and occur in patients whose bones were previously stable on treatment.

The mitigation: Transition to a bisphosphonate (alendronate, risedronate, or zoledronic acid) after the last denosumab dose. This is not optional; it is required. The FDA black box warning exists because patients and providers were discontinuing without this plan.

Romosozumab (Evenity): Cardiovascular Risk Breakdown

FDA black box warning: Increased risk of myocardial infarction, stroke, and cardiovascular death.

Study data from the ARCH trial:

2.5% cardiovascular event rate in romosozumab group
1.9% in alendronate control group
Absolute increase: 0.6 percentage points
Risk concentrated in first year of treatment
Source

Who should avoid:

Prior MI or stroke within 12 months
High cardiovascular risk profiles

Context: The 0.6% absolute increase must be weighed against fracture prevention benefits. For a patient with high fracture risk and low cardiovascular risk, the tradeoff may favor treatment.

Osteonecrosis of the Jaw (ONJ): Rare and Context-Dependent

Actual incidence:

1 to 5 per 10,000 patient-years across antiresorptive therapies
Higher with IV bisphosphonates than oral
Higher with denosumab than bisphosphonates
Source

Risk factors:

Prior tooth extraction or dental implant while on therapy
Poor oral hygiene
Longer duration of treatment

Prevention:

Complete invasive dental work before starting therapy if possible. Maintain excellent oral hygiene. Inform all dentists that you take antiresorptive medication.

Comparative Effectiveness: Network Meta-Analysis Rankings

Vertebral Fracture Prevention (Most to Least Effective)

Based on pooled data from comparative trials: Source

Rank	Treatment	Relative Effectiveness
1	Romosozumab	Highest
2	Denosumab	High
3	Teriparatide / Zoledronic acid	Moderate-High
4	Alendronate / Risedronate	Moderate
5	Ibandronate / Raloxifene	Lower

Hip Fracture Prevention

Treatment	Risk Reduction vs Placebo
Zoledronic acid	40-53%
Denosumab	Similar to zoledronic
Alendronate	40-51%
Risedronate	30-40%

Source: PMID 32588816

Anabolic vs Antiresorptive: The Key Distinction

Antiresorptives (Bisphosphonates, Denosumab)

Mechanism: Inhibit osteoclasts (cells that break down bone)
Effect: Preserve existing bone; slow loss
Time to effect: 6-12 months for BMD stabilization
Duration: Long-term (years to decades)

Anabolics (Teriparatide, Abaloparatide, Romosozumab)

Mechanism: Stimulate osteoblasts (cells that build bone) OR dual action
Effect: Create new bone; increase density and strength
Time to effect: 3-6 months for measurable gains
Duration: Limited (12 months for romosozumab, 24 months for teriparatide)

Sequential therapy requirement: Anabolics must be followed by antiresorptives. Without this, gains are lost.

Duration Limits and Drug Holidays

Bisphosphonate Duration

Oral (alendronate, risedronate): Up to 10 years recommended maximum
IV zoledronic acid: Up to 6 years recommended maximum
Rationale: AFF risk increases with duration beyond 5 years

Drug Holiday Criteria

Considered for patients after 3-5 years if:

No fractures during treatment
BMD stabilized or improved
Fracture risk now moderate (not high)
Source

Note: This does NOT apply to denosumab. Denosumab cannot be “holidayed” without replacement therapy.

Glucocorticoid-Induced Osteoporosis: Special Case

For patients on long-term prednisone or similar steroids:

Effective options:

Denosumab
Teriparatide
Romosozumab (showed greater lumbar spine BMD gains than denosumab in head-to-head GIOP trials)

Source

Summary: Risk-Benefit by Drug

Drug	Fracture Reduction	Primary Risk	Risk Rate	Mitigation
Alendronate	40-70% vertebral, 40-51% hip	Atypical femur fracture, ONJ	AFF: 1-10/10,000 patient-years; ONJ: 1-5/10,000	Drug holiday at 3-5 years
Risedronate	Similar to alendronate	Atypical femur fracture, ONJ	Similar to alendronate	Drug holiday at 3-5 years
Zoledronic acid	40-53% hip	Atypical femur fracture, ONJ, acute phase reaction	AFF/ONJ similar; acute phase in 10-20% first dose	6-year maximum duration
Denosumab	39% better than alendronate	Rebound fractures if stopped	~7% without sequential therapy	Mandatory transition to bisphosphonate
Romosozumab	Highest efficacy	Cardiovascular events	+0.6% absolute vs placebo first year	Contraindicated with recent MI/stroke
Teriparatide	Superior to bisphosphonates	Osteosarcoma (theoretical), hypercalcemia	No confirmed human osteosarcoma; rat studies only	2-year limit; sequential therapy required

Sources

PMID 30657216 — Treating osteoporosis to prevent fractures: current concepts
PMID 32588816 — Denosumab, raloxifene, romosozumab and teriparatide systematic review
PMID 31626995 — Clinical effectiveness network meta-analysis
PMID 38753892 — Comparative effectiveness denosumab vs alendronate
PMID 39448137 — Prevention and Management of Denosumab Discontinuation
PMID 36088628 — Multiple Vertebral Fractures After Denosumab Discontinuation
PMID 33924496 — Romosozumab cardiovascular safety FDA analysis
PMID 38512565 — Comparative analysis of anti-osteoporosis medications
PMID 39312040 — Teriparatide vs bisphosphonates meta-analysis
PMID 34679224 — Risk factors for bisphosphonate-associated AFF
PMID 27179251 — Long-term bisphosphonate safety
PMID 33442127 — Osteonecrosis of the jaw incidence
PMID 28760963 — Bisphosphonate effects on bone toughening mechanisms
PMID 40015362 — Publication bias in AFF and ONJ reporting
PMID 32060897 — Treatment failure definitions and management
PMID 41678248 — Glucocorticoid-induced osteoporosis treatment
PMID 35362725 — Romosozumab sequential therapy outcomes

This document presents quantitative findings from peer-reviewed research. Treatment decisions require individualized clinical assessment.